EcoDrugPlus

Cytidine Deaminase-Like

Ensembl ID : ENSPNAG00000012141
Gene Symbol: LOC108436250
3 Cross references
156 Possible Orthologues:

Cytidine Deaminase-Like

Ensembl ID : ENSPNAG00000022445
Gene Symbol: LOC108433378
3 Cross references
198 Possible Orthologues:

Cytochrome P450 26a1

Ensembl ID : ENSPNAG00000011729
Gene Symbol: LOC108412396
3 Cross references
194 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSPNAG00000001660
Gene Symbol: LOC108414959
2 Cross references
564 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSPNAG00000001962
Gene Symbol: LOC108413708
3 Cross references
574 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSPNAG00000002015
Gene Symbol: LOC108413711
2 Cross references
564 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSPNAG00000022214
Gene Symbol: LOC108430602
3 Cross references
536 Possible Orthologues:

Cytochrome P450 3a30-Like

Ensembl ID : ENSPNAG00000011897
Gene Symbol: LOC108413706
3 Cross references
574 Possible Orthologues:

Cytochrome P450 3a40-Like

Ensembl ID : ENSPNAG00000011930
Gene Symbol: LOC108413709
2 Cross references
564 Possible Orthologues:

Cytochrome P450 3a56-Like

Ensembl ID : ENSPNAG00000001594
Gene Symbol: LOC108414960
2 Cross references
564 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSPNAG00000000216
Gene Symbol: CYP19A1
3 Cross references
244 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSPNAG00000021262
Gene Symbol: LOC108436134
2 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).